1969
DOI: 10.1093/ml/l.1.8
|View full text |Cite
|
Sign up to set email alerts
|

A. H. Fox Strangways

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
3
0

Year Published

1979
1979
2019
2019

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 0 publications
0
3
0
Order By: Relevance
“…Actually, Howes et al [1969] ob served that after 3 h of treatment of Tricho monas foetus cultures with 20 //g/ml, there was an appreciable reduction in the number of individuals, effect much more pro nounced after 12 h. Likewise, they obtained similar results with Trichomonas vaginalis. These authors also reported that for the tro phozoites of Entamoeba histolytica the min imal inhibitory concentration was 40 /<g/ml and the minimal lethal concentration was 80 /¿g/ml.…”
Section: Discussionmentioning
confidence: 76%
See 1 more Smart Citation
“…Actually, Howes et al [1969] ob served that after 3 h of treatment of Tricho monas foetus cultures with 20 //g/ml, there was an appreciable reduction in the number of individuals, effect much more pro nounced after 12 h. Likewise, they obtained similar results with Trichomonas vaginalis. These authors also reported that for the tro phozoites of Entamoeba histolytica the min imal inhibitory concentration was 40 /<g/ml and the minimal lethal concentration was 80 /¿g/ml.…”
Section: Discussionmentioning
confidence: 76%
“…Therefore, it is very likely that the cytotoxic effect of tinidazole be also much more effective in anaerobic condi tions. In that way, it could be explained the fact that the nitroimidazoles are inactive against different species of Trypanosoma [Howes et al, 1969;Prince et al, 1969].…”
Section: Discussionmentioning
confidence: 99%
“…It is in clinical trials for use in combination therapies for several different types of carcinomas [37,56,57]. Phenoxodiol is in phase II clinical trial for the treatment of ovarian cancer [37,58,59]. Vadimezan (DMXAA) is a flavone acetic acid derivative with vascular-disrupting activity, which has been evaluated for non-small-cell lung cancer and showed encouraging results in phase II clinical trials, although the results of phase III were not promising [60].…”
Section: Discussionmentioning
confidence: 99%